EGFR and gastric cancer: In a multicenter, RCT conducted by Rao et al. (18), mastuzumab (anti-EGFR monoclonal antibody) was added to epirubicin, cisplatin, and capecitabine to test the efficacy when treating advanced gastric cancer.